Start Trial ->
Intercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA)
February 2, 2024
OCA 25 mg met the agreed primary endpoint of improvement in liver fibrosis without worsening of NASH at 18 months (p
Simplest Unusual Options Activity Platform for traders. SweepCast can be used for swing or day traders who are looking to get insights on where Smart money is flowing, sign up today.
Terms & Privacy